Quiescent Proliferative Diabetic Retinopathy

A post hoc analysis of a subset of patients with diabetic macular edema treated with an anti-VEGF agent in the VISTA phase 3 trial identified a moderate correlation between significant reductions in macular retinal nonperfusion with improvements in best corrected visual acuity and central retinal thickness, according to a presenter at the virtual Association for Research in Vision and Ophthalmology meeting.